This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ACHN Achillion Pharmaceuticals (ACHN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Achillion Pharmaceuticals Stock (NASDAQ:ACHN) 30 days 90 days 365 days Advanced Chart Get ACHN alerts:Sign Up Key Stats Today's Range$6.76▼$6.7650-Day Range$6.76▼$6.7652-Week Range$2.06▼$7.01VolumeN/AAverage Volume8.44 million shsMarket Capitalization$946.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAchillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in New Haven, Connecticut.Read More… Receive ACHN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Achillion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ACHN Stock News HeadlinesKim P. Kamdar's Net WorthMarch 30, 2024 | benzinga.comLexicon Pharmaceuticals (NASDAQ: LXRX)May 20, 2023 | fool.comNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.June 30 at 2:00 AM | American Alternative (Ad)Gilead Sciences Buying Achillion Was Twitter Speculation at Its FinestFebruary 19, 2023 | thestreet.comACHN_old Historical DataSeptember 18, 2022 | investing.comWhy Achillion Pharmaceuticals (ACHN) Stock Is Up in After-Hours Trading TodayJanuary 13, 2022 | thestreet.comJim Cramer's 'Mad Money' Recap: Here's Next Week's Game PlanJanuary 12, 2022 | thestreet.comSee More Headlines ACHN Stock Analysis - Frequently Asked Questions How were Achillion Pharmaceuticals' earnings last quarter? Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) released its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.02. What other stocks do shareholders of Achillion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Achillion Pharmaceuticals investors own include Chesapeake Energy (CHKAQ), Skyworks Solutions (SWKS), Madrigal Pharmaceuticals (MDGL), Noble (NEBLQ), Gilead Sciences (GILD), Eiger BioPharmaceuticals (EIGR) and Meta Platforms (META). Company Calendar Last Earnings11/07/2019Today6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ACHN CIK1070336 Webwww.achillion.com Phone203-624-7000FaxN/AEmployees56Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$70.27 million Net MarginsN/A Pretax MarginN/A Return on Equity-30.95% Return on Assets-29.09% Debt Debt-to-Equity Ratio0.01 Current Ratio8.96 Quick Ratio8.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.92 per share Price / Book3.52Miscellaneous Outstanding Shares140,047,000Free FloatN/AMarket Cap$946.72 million OptionableOptionable Beta1.59 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:ACHN) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achillion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Achillion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.